Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer; SOPHIA

Press/Media

Period2 Oct 2018

Media coverage

1

Media coverage

  • TitleMargetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer; SOPHIA
    Media name/outletClinical Trials.gov
    Country/TerritoryUnited States
    Date2/10/18
    PersonsMary Kemeny